Skip to main content

Table 1 Inclusion and exclusion criteria for the study population

From: Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment

Inclusion criteria

   • aged 6–18 years

   • history of allergic rhinitis for at least 1 year

   • IgE antibodies ≥0.7 kU/l to house dust mite

   • no use of nasal steroids in the month before start of baseline measurements

   • rhinitis symptom score of at least 4 out of 12 during last 3 months

   • signed informed consent

Exclusion criteria

   • severe asthma (requiring 800 mcg budesonide daily or equivalent for other inhaled steroids; or requiring >3 courses of oral prednisone/prednisolone in previous year or required hospital stay for asthma in previous year)

   • sensitization to pets present at home (IgE antibodies ≥0.7 kU/l)

   • planned surgery of nasal cavity

   • having received immunotherapy in past 3 years

   • language barrier

   • contraindications to sublingual immunotherapy (as supplied by the manufacturer)